Morgan Stanley boosts Chemomab (CMMB) shares 1277% in Q2 2025;...
Key Takeaways Analyst upgrades from Oppenheimer and Roth MKM signal increased confidence in Chemomab’s lead candidate, nebokitug, and potential for M&A or partnership activity. Institutional holdings surged, with Morgan Stanley...